# Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease

> **NCT05292950** · PHASE1,PHASE2 · TERMINATED · sponsor: **Arrowhead Pharmaceuticals** · enrollment: 78 (actual)

## Conditions studied

- Asthma
- Chronic Obstructive Pulmonary Disease

## Interventions

- **DRUG:** ARO-MUC5AC
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05292950
- **Lead sponsor:** Arrowhead Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-27
- **Primary completion:** 2024-11-12
- **Final completion:** 2024-11-12
- **Target enrollment:** 78 (ACTUAL)
- **Why stopped:** Sponsor business decision
- **Last updated:** 2025-11-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05292950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05292950, "Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05292950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*